Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Treatment landscape and outcome of myeloproliferative neoplasms in asia: Interim analysis of the Asian myeloproliferative neoplasm registry

View Full Paper
Ask AI
Bookmark
Share

Authors

VLVivian LiQZQi ZhangPCPaul K.S. Chan

Discussion

Loading...

Member takes

Overview

Retrospective and prospective cohort analysis highlights that pegylated-interferon alfa improves overall survival in myeloproliferative neoplasms patients.

Key Points

  • Patients treated with pegylated-interferon alfa exhibited improved overall survival compared to those who did not, indicating its importance in management.
  • Overall survival for polycythemia vera and essential thrombocythemia was significantly higher when treated with pegylated-interferon alfa among 969 patients.
  • Observational multicenter cohort analysis showed differing treatment impacts across myeloproliferative neoplasms with respect to acute myeloid leukemia risk.
  • The findings point to the need for further research to assess treatment efficacy across subgroups in myeloproliferative neoplasms.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d790https://doi.org/10.1182/blood-2025-2041
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of pegylated interferon alfa-2b in myeloproliferative neoplasms: A multicenter retrospective study of 210 patients2025
  2. 2Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms2025 · 4 citations
  3. 3Interferon alfa treatment of early primary myelofibrosis is associated with improved overall survival2025
  4. 4[A new era in the treatment of myeloproliferative neoplasms].2025
  5. 5Ten-year journey with myelofibrosis: real-world data and clinical outcomes from a tertiary care center2025